

## DMP title

**Project Name** FWO 12W7822N DMP - DMP title

**Project Identifier** 12W7822N

**Grant Title** 12W7822N

**Principal Investigator / Researcher** Steve Peigneur

**Project Data Contact** 016323418, steve.peigneur@kuleuven.be

**Institution** KU Leuven

### 1. General Information

#### **Name applicant**

Steve Peigneur

#### **FWO Project Number & Title**

**12W7822N**

**FUNCTIONAL CHARACTERISATION OF TRANSIENT RECEPTOR POTENTIAL VANILLOID (TRPV2) AS A POTENTIAL NEW TARGET FOR ENDOMETRIAL CANCER**

#### **Affiliation**

- KU Leuven

### 2. Data description

**Will you generate/collect new data and/or make use of existing data?**

- Generate new data

**Describe in detail the origin, type and format of the data (per dataset) and its (estimated) volume. This may be easiest in a table (see example) or as a data flow and per WP or objective of the project. If you reuse existing data, specify the source of these data. Distinguish data types (the kind of content) from data formats (the technical format).**

#### **Work Package 1: Identification of novel TRPV2 modulators**

A large number of venom and plant extractions will be investigated using a fluorescence-based THC-induced assay. In this assay, HEK293 cells stably expressing mouse TRPV2 are transferred into wells of a microtiter plate and loaded with the Ca<sup>2+</sup>-sensitive fluorescent dye fura-2. Moreover, whole-cell patch-clamp measurements on HEK cells overexpressing mouse and human TRPV2 will be performed to investigate potential TRPV2 species differences. We will evaluate the effect of selected compounds on the responses of primary stromal cells of different species. Primary endometrial stromal cultures will be isolated from human, and mice (TRPV2<sup>+/+</sup> and TRPV2<sup>-/-</sup>), and responses will be tested using Fura-2 mediated Ca<sup>2+</sup>-imaging and validated by whole-cell patch-clamp experiments.

#### **WP2: Structure-function activity relationship investigation (QSARs): Biophysical characterisation TRPV2**

Chimaeras between mouse and human TRPV2 will be constructed and their functionality assessed by patch-clamp experiments in a heterologous overexpressing system.

#### **WP3: Assessment of TRPV2 as a target for the treatment of endometrial cancer**

##### **Task 3.1 TRPV2 agonist therapy**

The optimized and in-depth characterized lead compounds will be used to investigate the involvement of TRPV2 *in vitro* and *in vivo* proliferation, migration and differentiation assays of control and malignant endometrial cells. To this end, we will test both TRPV2 agonists (THC and outcome WP1) and antagonists (LICR1 and outcome WP1) in proliferation, migration and differentiation protocols. To validate the anti-tumour properties of TRPV2 targeting compounds, we will use endometrial tumour cell lines with a variable EMT status and patient-derived endometrial cancer organoids (EC-O).

Work package	Origin of data	Type of data	File format	Estimated Volume
<b>WP 1:</b> Task 1.1: Exploration of natural sources for novel TRPV2 ligands	Computer, HPLC chromatogram	Numerical and image, ...	xlsx, jpeg	1 GB
Task 1.2: Validation of hit compounds & Task 1.3: Selectivity profile determination of hit compounds	Computer electrophysiological, experimental data	electrophysiological, experimental data, numerical	Analyzed data (Xlsx) Raw data (Xlsx)	500 MB
<b>WP 2:</b> Task 2.1: Molecular elucidation of the difference in compound sensitivity between human TRPV2 and rat TRPV2 & Task 2.2: Identifying the lead compound's mechanism of action	Computer	electrophysiological, experimental data, numerical	Analyzed data (Xlsx) Raw data (Xlsx)	500 MB
	Computer	Calcium imaging of primary stromal cells	Raw data (nd2)  Exported data (xlsx)  Analysed data (xlsx)  Images & figures (tiff, jpeg)	10 GB/file  10 MB/file  10 MB/file  1 MB/file

<b>WP3:</b> Assessment of TRPV2 as a target for the treatment of endometrial cancer endometrial tumour cell lines	computer	Calcium imaging of primary stromal cells	Raw data (nd2)	10 GB/file
			Exported data (xlsx)	10 MB/file
			Analysed data (xlsx)	10 MB/file
			Images & figures (tiff, jpeg)	1 MB/file
<b>WP3:</b> endometrial cancer-derived organoids	Computer, automated analysis of cell behavior	Migration and invasion assays in cell imaging platform incucyte	Raw data (nd2, Nikon)	10 GB/file
			Exported data (xlsx)	10 MB/file
			Analysed data (xlsx)	10 MB/file
			Images & figures (tiff, jpeg)	1 MB/file

### 3. Legal and ethical issues

**Will you use personal data? If so, shortly describe the kind of personal data you will use. Add the reference to your file in KU Leuven's Register of Data Processing for Research and Public Service Purposes (PRET application). Be aware that registering the fact that you process personal data is a legal obligation.**

- No

Privacy Registry Reference:

Short description of the kind of personal data that will be used:

**Are there any ethical issues concerning the creation and/or use of the data (e.g. experiments on humans or animals, dual use)? If so, add the reference to the formal approval by the relevant ethical review committee(s)**

- No

**Does your work possibly result in research data with potential for tech transfer and valorisation? Will IP restrictions be claimed for the data you created? If so, for what data and which restrictions will be asserted?**

- No

**Do existing 3rd party agreements restrict dissemination or exploitation of the data you (re)use? If so, to what data do they relate and what restrictions are in place?**

- No

#### **4. Documentation and metadata**

**What documentation will be provided to enable reuse of the data collected/generated in this project?**

All data generated will follow standardized protocols. Metadata will be documented by the research and technical staff at the time of data collection and analysis. Data will be stored in equipment-specific files on the KU Leuven Large Volume storage, with names that include the date, cell type and experiment file number. Metadata files generated by the equipment are saved on the KU Leuven Large Volume storage in the folder corresponding to the date of acquisition. Metadata generated by the researcher are stored in hard copy notebooks and uploaded and saved in the electronic lab notebook under the acquisition date.

**Will a metadata standard be used? If so, describe in detail which standard will be used. If no, state in detail which metadata will be created to make the data easy/easier to find and reuse.**

- Yes

Since there is no formally acknowledged metadata standard specific to our discipline, the DDI standard (Data Documentation Initiative) will be used. Future-wise, we will investigate whether a suitable metadata standard for electrophysiology data is available.

#### **5. Data storage and backup during the FWO project**

**Where will the data be stored?**

Data are temporarily stored at the internal storage of equipment-specific computers. Patch clamp data are temporarily stored on the applicant's personal computer. After acquisition, data are saved on the KU Leuven Large Volume Storage and duplicated on external hard drives on a 2 weekly base.

**How is backup of the data provided?**

Data is backed up on the KU Leuven Large Volume Storage facility in a weekly automated process. In parallel, copies are taken every 2 weeks on external hard discs.

**Is there currently sufficient storage & backup capacity during the project? If yes, specify concisely. If no or insufficient storage or backup capacities are available then explain how this will be taken care of.**

- Yes

The KU Leuven Large Volume Storage facility has a capacity of 6 PB. If required, more space can be purchased in blocks of 5 TB.

**What are the expected costs for data storage and back up during the project? How will these costs be covered?**

Expected costs for data storage are estimated at 1500 euro/3 years. These costs will be covered by the host lab.

**Data security: how will you ensure that the data are securely stored and not accessed or modified by unauthorized persons?**

Raw data are stored on the KU Leuven Large Volume Storage service and secured by KU Leuven security groups. Analyzed data are stored on password-protected KU Leuven personal computers and hard drives.

#### **6. Data preservation after the FWO project**

**Which data will be retained for the expected 5 year period after the end of the project? In case only a selection of the data can/will be preserved, clearly state the reasons for this (legal or contractual restrictions, physical preservation issues, ...).**

All relevant research data expected to be generated during this project are retained for a period of minimally 10 years after the end of the project, in a safe, secure & sustainable way for purposes of reproducibility, verification, and potential reuse.

**Where will the data be archived (= stored for the longer term)?**

The data will be stored on the university's central servers (with automatic back-up procedures) for at least 10 years, conform the KU Leuven RDM policy. The anonymised transcripts will be made available through Harvard Dataverse. Access will be considered after a request is submitted explaining the planned reuse. Only uses for research purposes will be allowed and commercial reuse will be excluded.

**What are the expected costs for data preservation during the retention period of 5 years? How will the costs be covered?**

Expected costs for data storage are expected to be 1500 euro for 3 years. For backup, the current KU Leuven tariffs are around 175 euro/TB/year. These costs will be covered by the hosting lab.

**7. Data sharing and reuse**

**Are there any factors restricting or preventing the sharing of (some of) the data (e.g. as defined in an agreement with a 3rd party, legal restrictions)?**

- No

**Which data will be made available after the end of the project?**

The anonymised transcripts will be published in Harvard Dataverse.

**Where/how will the data be made available for reuse?**

The anonymised transcripts will be published in Harvard Dataverse.

**When will the data be made available?**

- Immediately after the end of the project

The anonymised transcripts will be published in Harvard Dataverse.

**Who will be able to access the data and under what conditions?**

The anonymised transcripts will be made available through Harvard Dataverse. Access will be considered after a request is submitted explaining the planned reuse. Only uses for research purposes will be allowed and commercial reuse will be excluded.

**What are the expected costs for data sharing? How will the costs be covered?**

No costs are expected for data sharing.

**8. Responsibilities**

**Who will be responsible for data documentation & metadata?**

Steve Peigneur

**Who will be responsible for data storage & back up during the project?**

Steve Peigneur

**Who will be responsible for ensuring data preservation and reuse ?**

Jan Tytgat

**Who bears the end responsibility for updating & implementing this DMP?**

The PI (Jan Tytgat) bears the end responsibility of updating & implementing this DMP.